dc.contributor
Institut Català de la Salut
dc.contributor
[Hoff LS] School of Medicine, Universidade Potiguar (UnP), Natal, Brazil. [Ravichandran N] Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. [Shinjo SK, Junior JG] Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil. [Day J] Department of Rheumatology, Royal Melbourne Hospital, Parkville, Australia. Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. Department of Medical Biology, University of Melbourne, Parkville, Australia. [Sen P] Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, India. [O'Callaghan AS] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Hoff, Leonardo
dc.contributor.author
Ravichandran, Naveen
dc.contributor.author
Day, Jessica
dc.contributor.author
Gonçalves Júnior, Jucier
dc.contributor.author
Selva O'Callaghan, Albert
dc.contributor.author
Sen, Parikshit
dc.contributor.author
Shinjo, Samuel
dc.date.accessioned
2025-10-24T10:42:18Z
dc.date.available
2025-10-24T10:42:18Z
dc.date.issued
2023-02-15T13:07:35Z
dc.date.issued
2023-02-15T13:07:35Z
dc.identifier
Hoff LS, Ravichandran N, Shinjo SK, Day J, Sen P, Junior JG, et al. COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Disease. Rheumatol Int. 2023 Jan;43:47–58.
dc.identifier
https://hdl.handle.net/11351/8994
dc.identifier
10.1007/s00296-022-05229-7
dc.identifier
000871168700001
dc.identifier.uri
https://hdl.handle.net/11351/8994
dc.description.abstract
COVID-19; Idiopathic inflammatory myopathies; SARS-CoV-2 vaccination
dc.description.abstract
COVID-19; Miopatías inflamatorias idiopáticas; Vacunación SARS-CoV-2
dc.description.abstract
COVID 19; Miopaties inflamatòries idiopàtiques; Vacunació SARS-CoV-2
dc.description.abstract
Objectives
We aimed to compare the spectrum and severity of COVID-19 and vaccine breakthrough infections (BIs) among patients with IIMs, other systemic autoimmune and inflammatory diseases (SAIDs), and healthy controls (HCs).
Methods
This is a cross-sectional study with data from the COVAD study, a self-reported online global survey that collected demographics, COVID-19 history, and vaccination details from April to September 2021. Adult patients with at least one COVID-19 vaccine dose were included. BIs were defined as infections occurring > 2 weeks after any dose of vaccine. Characteristics associated with BI were analyzed with a multivariate regression analysis.
Results
Among 10,900 respondents [42 (30–55) years, 74%-females, 45%-Caucasians] HCs were (47%), SAIDs (42%) and IIMs (11%). Patients with IIMs reported fewer COVID-19 cases before vaccination (6.2%-IIM vs 10.5%-SAIDs vs 14.6%-HC; OR = 0.6, 95% CI 0.4–0.8, and OR = 0.3, 95% CI 0.2–0.5, respectively). BIs were uncommon (1.4%-IIM; 1.9%-SAIDs; 3.2%-HC) and occurred in 17 IIM patients, 13 of whom were on immunosuppressants, and 3(18%) required hospitalization. All-cause hospitalization was higher in patients with IIM compared to HCs [23 (30%) vs 59 (8%), OR = 2.5, 95% CI 1.2–5.1 before vaccination, and 3 (18%) vs 9 (5%), OR = 2.6, 95% CI 1.3–5.3 in BI]. In a multivariate regression analysis, age 30–60 years was associated with a lower odds of BI (OR = 0.7, 95% CI 0.5–1.0), while the use of immunosuppressants had a higher odds of BI (OR = 1.6, 95% CI 1.1–2.7).
Conclusions
Patients with IIMs reported fewer COVID-19 cases than HCs and other SAIDs, but had higher odds of all-cause hospitalization from COVID-19 than HCs. BIs were associated with the use of immunosuppressants and were uncommon in IIMs.
dc.format
application/pdf
dc.relation
Rheumatology International;43
dc.relation
https://doi.org/10.1007/s00296-022-05229-7
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
COVID-19 (Malaltia) - Vacunació
dc.subject
Malalties autoimmunitàries
dc.subject
DISEASES::Immune System Diseases::Autoimmune Diseases
dc.subject
DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunotherapy, Active::Vaccination
dc.subject
ENFERMEDADES::enfermedades del sistema inmune::enfermedades autoinmunes
dc.subject
ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunoterapia activa::vacunación
dc.title
COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
